iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin gets USFDA approval for Tiotropium Dry Powder Inhaler

21 Jun 2023 , 02:46 PM

Lupin Limited announced that the United States Food and Drug Administration (USFDA) has granted approval for its Abbreviated New Drug Application for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule. It is a generic equivalent of Boehringer Ingelheim Pharmaceuticals, Inc.’s Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule.

Lupin’s Pithampur facility in India will manufacture this product.

Vinita Gupta, the CEO of Lupin, expressed great satisfaction with the recent approval received from the USFDA for the generic version of Spiriva HandiHaler. This approval reinforces their dedication to addressing the unmet requirements of patients worldwide. 

It is noteworthy that this is the first approval for a generic version of Spiriva HandiHaler in the U.S., and it also marks the first approval of a Dry Powder Inhaler (DPI) from India for the U.S. market. The company considers this a significant achievement in their efforts to establish a strong respiratory franchise on a global scale.

In the United States, Tiotropium Bromide Inhalation Powder (Spiriva HandiHaler) had an estimated annual sales of USD 1,264 million (IQVIA MAT Mar 2023).

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Lupin
  • Lupin News
  • Lupin Tiotropium
  • Lupin Updates
  • Lupin USFDA Approval
  • USFDA approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.